Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Kana Yamanashi 2 Articles
IBD
Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
Shinya Fukushima, Takehiko Katsurada, Mutsumi Nishida, Satomi Omotehara, Kensuke Sakurai, Kana Yamanashi, Reizo Onishi, Naoya Sakamoto
Intest Res 2024;22(1):82-91.   Published online January 29, 2024
DOI: https://doi.org/10.5217/ir.2023.00093
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Transabdominal ultrasonography (US) helps evaluate Crohn’s disease (CD) activity. We investigated whether the US could predict subsequent adverse outcomes for patients with CD in clinical remission.
Methods
This single-center retrospective study included patients with CD in clinical remission who underwent US between April 2011 and April 2021, focusing on the predictability of subsequent adverse outcomes within 5 years. We used the US-CD, which was calculated using multiple US findings. Predictive variables were assessed using Cox proportional hazards regression analysis, and the predictive value was evaluated using receiver operating characteristic curves.
Results
Seventy-three patients were included. During a median follow-up of 1,441 days (range, 41–1,825 days), 16.4% (12/73) experienced clinical relapse, 9.6% (7/73) required endoscopic balloon dilation (EBD), 58.9% (43/73) required enhanced treatment, and 20.5% (15/73) underwent surgery. In the multivariate analysis, US-CD was significantly associated with clinical relapse (P= 0.038) and the need for enhanced treatment (P= 0.005). The area under the receiver operating characteristic curve for predicting clinical relapse and the need for EBD was 0.77 and 0.81, respectively, with US-CD (cutoff value = 11), and that for requiring enhanced treatment was 0.74 with US-CD (cutoff value = 6). Patients with US-CD ≥ 11 demonstrated a significantly higher occurrence of clinical relapse (P= 0.001) and EBD (P= 0.002) within 5 years. Patients with US-CD ≥ 6 experienced a significantly higher likelihood of requiring enhanced treatment (P< 0.001) within 5 years.
Conclusions
High US-CD is associated with subsequent adverse outcomes in patients with CD.
  • 2,224 View
  • 127 Download
Close layer
IBD
Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, Shinsuke Otagiri, Kana Yamanashi, Kazunori Nagashima, Reizo Onishi, Keiji Yagisawa, Haruto Nishimura, Takahiro Ito, Atsuo Maemoto, Naoya Sakamoto
Intest Res 2022;20(1):78-89.   Published online January 22, 2021
DOI: https://doi.org/10.5217/ir.2020.00124
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effectiveness of zinc acetate hydrate (ZAH; Nobelzin) in IBD patients with zinc deficiency.
Methods
IBD patients with zinc deficiency who received ZAH from March 2017 to April 2020 were registered in this 2-center, retrospective, observational study. Changes in serum zinc levels and disease activity (Crohn’s Disease Activity Index [CDAI]) before and after ZAH administration were analyzed.
Results
Fifty-one patients with Crohn’s disease (CD, n = 40) or ulcerative colitis (UC, n = 11) were registered. Median serum zinc level and median CDAI scores significantly improved (55.5–91.0 μg/dL, P< 0.001; 171.5–129, P< 0.001, respectively) in CD patients 4 weeks after starting ZAH administration. Similarly, median serum zinc levels and CDAI scores significantly improved (57.0–81.0 μg/dL, P< 0.001; 177–148, P= 0.012, respectively) 20 weeks after starting ZAH administration. Similar investigations were conducted in groups where no treatment change, other than ZAH administration, was implemented; significant improvements were observed in both serum zinc level and CDAI scores. Median serum zinc levels in UC patients 4 weeks after starting ZAH administration significantly improved from 63.0 to 94.0 μg/dL (P= 0.002), but no significant changes in disease activity were observed. One patient experienced side effects of abdominal discomfort and nausea.
Conclusions
ZAH administration is effective in improving zinc deficiency and may contribute to improving disease activity in IBD.

Citations

Citations to this article as recorded by  
  • Dietary Zinc Ameliorates TNBS-Induced Colitis in Mice Associated with Regulation of Th1/Th2/Th17 Balance and NF-κB/NLRP3 Signaling Pathway
    Changlin Wen, Jiayu Wang, Zhenhua Sun, Rao Zhong, Mengjie Li, Xuemei Shen, Qiaobo Ye, Kaihua Qin, Xi Peng
    Biological Trace Element Research.2024; 202(2): 659.     CrossRef
  • Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn’s Disease: New Tools for New Approaches
    Fernando Rizzello, Ilaria Maria Saracino, Paolo Gionchetti, Maria Chiara Valerii, Chiara Ricci, Veronica Imbesi, Eleonora Filippone, Irene Bellocchio, Nikolas Konstantine Dussias, Thierry Dervieux, Enzo Spisni
    Nutrients.2024; 16(2): 280.     CrossRef
  • Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer
    Yusuke Seiki, Kenji Ikezawa, Ko Watsuji, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Miki Ishibashi, Kazuyoshi Ohkawa
    International Journal of Clinical Oncology.2024; 29(8): 1173.     CrossRef
  • Zinc and Inflammatory Bowel Disease: From Clinical Study to Animal Experiment
    Xi Peng, Yingxiang Yang, Rao Zhong, Yuexuan Yang, Fang Yan, Na Liang, Shibin Yuan
    Biological Trace Element Research.2024;[Epub]     CrossRef
  • Role of Combination Treatment of Aspirin and Zinc in DMH-DSS-induced Colon Inflammation, Oxidative Stress and Tumour Progression in Male BALB/c Mice
    Singothu Siva Nagendra Babu, Shivani Singla, Gopabandhu Jena
    Biological Trace Element Research.2023; 201(3): 1327.     CrossRef
  • Retrospective study on the therapeutic efficacy of zinc acetate hydrate administration to patients with hypozincemia-induced dysgeusia
    Tomoaki Shintani, Kouji Ohta, Toshinori Ando, Yasutaka Hayashido, Souichi Yanamoto, Mikihito Kajiya, Hideki Shiba
    BMC Oral Health.2023;[Epub]     CrossRef
  • Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
    Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
    Nutrients.2023; 15(17): 3824.     CrossRef
  • Prevalence of Zinc Deficiency in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
    Roberta Zupo, Annamaria Sila, Fabio Castellana, Roberto Bringiotti, Margherita Curlo, Giovanni De Pergola, Sara De Nucci, Gianluigi Giannelli, Mauro Mastronardi, Rodolfo Sardone
    Nutrients.2022; 14(19): 4052.     CrossRef
  • 7,400 View
  • 493 Download
  • 9 Web of Science
  • 8 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP